Production of antibodies to HIV

Details Production of antibodies to HIV Production of antibodies to HIV

1987-09-08

1991-05-28

Moezie, F. T.

Drug, bio-affecting and body treating compositions

Lymphokine

424 855, 424 858, 424 8591, 530324, 530325, 530326, 530327, 530328, 530329, 530387, 530388, A61K 3912, A61K 3702

Patent

active

050193872

DESCRIPTION:

BRIEF SUMMARY
the envelope glycoprotein of HIV.
In yet another embodiment, the present invention comprises a method of producing immunity to HIV comprising administering the above-described conjugate to a mammal.
In another embodiment, the present invention comprises a method of detecting the presence of anti-gp120 antibodies in biological test samples .


BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Recombinant proteins and relation to synthetic peptides.
FIG. 2. Reactivity of AIDS patient antibodies to synthetic peptides.
FIG. 3. Reactivity to gp120 of antibodies from HIV+ patient purified over synthetic peptide affinity columns. (FIG. 3A) RIP assay of bound antibodies from the SP-10 (lane 1), SP-10A (lane 2), SP-11 (lane 3), SP-14 (lane 4), SP-15 (lane 5) and SP-22 (lane 6) affinity columns tested with gp120-III.sub.B. (FIG. 3B) Reactivity to the surface of H-9 cells infected with HTLV-III.sub.B in indirect immunofluorescence assays.
FIG. 4. Neutralization of HTLV-III.sub.B by goat anti-SP-10 antisera.
FIG. 5. Isolate specific neutralization of HIV. Ability of ( ) goat anti-SP-10 antiserum, ( .circle. ) pre-immune goat serum and ( ) AIDS patient serum to neutralize four different HIV isolates (FIG. 5A) HTLV-III.sub.B (FIG. 5B) HTLV-III.sub.RF (FIG. 5C) HTLV-III.sub.MN (FIG. 5D) HTLV-III.sub.SC.
FIG. 6. Binding of goat anti-SP-10 serum to HTLV-III.sub.B - but not to HTLV-III.sub.RF -infected H9 T cells. (FIG. 6A) Goat anti-SP-10 serum (1:200) reacted with 40% of HTLV-III.sub.B -infected H9 T cells compared to HTLV-III.sub.B -infected H9 cells incubated with control (prebleed) goad serum (1:200). (FIG. 6B) Neither goat anti-SP-10 nor control (prebled) serum (1:50) reacted with noninfected H9 T cells. (FIG. 6C) Neither control (prebleed) nor anti-SP-10 serum (1:50) bound to H9 T cells infected with the HTLV-III.sub.RF isolate of HIV.


DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to peptides corresponding to immunogenic epitopes of HIV and synthetic vaccines made therefrom. These novel immunogenic agents are prepared by chemically synthesizing peptides sharing antigenic determinants with the envelope protein of HIV. The peptides are linked to carrier molecules (and/or are polymerized) rendering them suitable as vaccines. These vaccines are useful for immunization against AIDS when administered to mammals, for example, by the parenteral route.
It was determined that peptides that should be studied for immunogenic potential included those corresponding to hydrophilic, charged regions of the HIV envelope glycoprotein. It was further determined that, of such peptides, those with predicted beta turns would likely be of particular importance. It was recognized that the formation of intrapeptide disulfide bonds would be useful in establishing native configurational determinants. Also, it was recognized that formation of interchain disulfide bonds would be useful in polymerizing peptide molecules so as to form larger, more immunogenic peptide aggregates.
Computer analysis of the predicted amino acid sequence of the envelope protein of the HTLVIII-.sub.B and ARV-2 isolates of HIV established the secondary structure and location of hydrophilic regions. Secondary structure was determined from the computer analysis using the method of Chou and Fasman (Biochemistry 13:211 and 13:222, 1974; Advances in Enzymology 47:45, 1978). Potential areas of beta turns were localized using the method of Rose (Nature 272:586, 1978). Hydrophilic regions of the envelope protein were identified by the technique of Rose and Roy (Proc. Nat'l. Acad. Sci. USA 77:4643, 1980).
The peptides of the instant invention correspond to, or are homologous with, B-cell epitopes present within the central region of the HIV isolate HTLV-III.sub.b envelope protein, or envelope protein of related HIV isolates. The peptides of the present invention are about 35 amino acids (units) or less in length, are hydrophilic, and when conjugated to appropriate carrier molecules, evoke the production in mammals of high titers (that is, advantageously, a reduct

REFERENCES:
Takahashi et al., J. of Exp. Med. 170:2023 (1989).
Palker et al., J. of Immunol. 142: 3612 (1989).
Girard et al., J. of Cell. Biochem. (Abst. L415), (1990), UCLA Symp. on Mol. & Cell. Biol., p. 150.
Weinhold et al., J. Cell. Biochem (Abst. L550), (1990), UCLA Symp. on Mol. & Cell. Biol., p. 180.
Palker et al., J. Cell., Biochm (Abst. L315), (1990), UCLA Symp. on Mol. & Cell Biol., p. 134.
Ratner et al., "Complete Nucleotide Sequence of the AIDS Virus, HTLV-III", Nature, vol. 313, pp. 277-284, 1985.
Palker et al., "A Conserved Region at the COOH Terminus of Human Immunodeficiency Virus gp 120 Envelop Protein Contains an immunodominant Epitope", Proc. Natl. Acad. Sci., U.S.A., vol. 84, pp. 2479-2483, 1987.
Ratner et al., Nature, vol. 313, pp. 277-284, 1985.
Peter Nawmark, "Problems with AIDS Vaccines", Nature, vol. 324, pp. 304-305, 1986.
Colin Norman, "AIDS Virus Presents Moving Target", Science, vol. 230, pp. 1357-1358, 1985.
Pert et al.; Proc. Natl. Acad. Sci., U.S.A., vol. 83, pp. 9254-9258, Dec. 1986; "Octapeptides Deducted from the Neuropeptide Receptor-Like Pattern of Antigen T4 in Brain Potently Inhibit Human Immunodeficiency Virus Receptor Binding and T-Cell Infectivity".
Sarin et al.; Science, vol. 232, pp. 1135-1138, May 30, 1986; "Neutralization of HTLV-III/LAV Replication by Antiserum to Thymosin.alpha..sub.1 ".
Kennedy et al.; Science, vol. 231, pp. 1556-1560, Mar. 28, 1986; "Antiserum to a Synthetic Peptide Recognizes the HTLV-III Envelope Glycoprotein".
Chanh et al.; The EMBO Journal, vol. 5, No. 11; "Induction of Anti-HIV Neutralizing Antibodies by Synthetic Peptides".
Putney et al.; Science, vol. 234, pp. 1392-1395, Dec. 12, 1986; HTLV-III/Lav14 neutralizing Antibodies to an E. Coli-Produced Fragment of the Virus Envelope.
Kennedy et al.; The Journal of Biological Chemistry, vol. 262, No. 12, pp. 5769-5774, Apr. 25, 1967; Use of a Resin-Bound Synthetic Peptide for Identifying a Neutralizing Antigenic Determinant Associated with the Human Immunodeficiency Virus Envelope.
Cease et al.; Proc. Natl. Acad. Sci., U.S.A., vol. 84, pp. 4249-4253, Jun. 1987, Helper T-Cell Antigenic Site Identification in the Acquired Immunodeficiency Syndrome Virus gp 120 Envelope Portein and Induction of Immunity in Mice to the Native Protein Using a 16-Residue Synthetic Peptide.
Ho et al.; Journal of Virology, vol. 61, No. 6, pp. 2024-2028, Jun. 1987; Human Immunodeficiency Virus Neutralizing Antibodies Recognize Several Conserved Domains on the Envelope Glycoproteins.
Krohn et al.; Proc. Natl. Acad. Sci., U.S.A., vol. 84, pp. 4994-4998, Jul. 1987, Spercific Cellular Immune Response and Neutralizing Antibodies in Goats Immunized with Native or Recombinant Envelope Proteins Derived from Human T-Lymphotropic Virus Type III.sub.B and in Human Immunodeficiency Virus-Infected Men.
Starcich et al.; Cell, vol. 45, pp. 637-648, Jun. 6, 1986; Identification and Characterization of Conserved and Variable Regions in the Envelope Gene of HTLV-III/LAV, the Retrovirus of Aids.
Robey et al.; Proc. Natl. Acad. Sci., U.S.A., vol. 83, pp. 7023-7027, Sep. 1986; Prospect for Prevention of Human Immunodeficiency Virus Infection: Purified 120-kDa Envelope Glycoprotein Induces Neutralizing Antibody.
Wang et al., Proc. Natl. Acad. Sci., U.S.A., vol. 83, pp. 6159-6163, Aug. 1986; Detection of Antibodies to Human T-Lymphotropic Virus Type III by Using a Sy
This invention was made with Government support under Grant No. CA43447 awarded by the National Institutes of Health. The Government may have certain rights in this invention.

Affiliated with

Also associated with

Rating

Production of antibodies to HIV does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Production of antibodies to HIV, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production of antibodies to HIV will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-35111